| | ||||||||||
| 1 | INN | Class | Route (list) | PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693) | Primary Target and PDB code of Protein-Drug complex | Targets from DrugCentral | Links | |||
| ENALAPRIL (has an active metabolite)
| ENALAPRIL |
CARDIOVASCULAR | ORAL | F 60 PERCENT | ANGIOTENSIN-CONVERTING ENZYME | Angiotensin-converting enzyme UNIPROT P12821 ACE more at DrugCentral | EMA | |||
| 2 | INN | Class | Route (list) | PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693) | Primary Target and PDB code of Protein-Drug complex | Targets from DrugCentral | Links | |||
| ENALAPRILAT (is an active metabolite)
| ENALAPRILAT | CARDIOVASCULAR | INJECTION | VD 24.7 LITER (65 KILOGRAM) PPB 38 PERCENT Cl 6.2 LITER / HOUR (65 KILOGRAM) HT 11 HOUR SOLUBILITY SPARINGLY SOLUBLE IN WATER | ANGIOTENSIN-CONVERTING ENZYME (ACE) PDB 1UZE (COMPLEX OF THE ANTI-HYPERTENSIVE DRUG ENALAPRILAT AND THE HUMAN TESTICULAR ANGIOTENSIN I-CONVERTING ENZYME) LIGAND CODE = EAL (link to the list of PDB complexes) Download experimental 3D coordinates of EAL with added hydrogens | Angiotensin-converting enzyme UNIPROT P12821 ACE more at DrugCentral | EMA | |||
